You are here

  • Home
  • Archive
  • Volume 28, Issue 2
  • FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps

Article metrics

Article menu
Download PDFPDF
EBM analysis
FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps

 

Online download statistics by month:

Online download statistics by month: April 2022 to April 2025

AbstractFullPdf
Apr 202215392516
May 202222504224
Jun 202218024618
Jul 2022478203
Aug 20223422110
Sep 20223362012
Oct 2022256105
Nov 2022253217
Dec 2022203114
Jan 202321090
Feb 2023182102
Mar 20233503014
Apr 20234143230
May 20233231212
Jun 202396117
Jul 202313893
Aug 20232191814
Sep 202310441
Oct 202315978
Nov 2023168175
Dec 2023158116
Jan 202413396
Feb 20249843
Mar 202419723
Apr 202420553
May 20245900
Jun 202422465
Jul 202414485
Aug 20248736
Sep 20246935
Oct 20249132
Nov 20249441
Dec 20249644
Jan 20258422
Feb 20254544
Mar 20251511
Apr 20251332
Total11634447253